Tag: AGLE
-
Aeglea BioTherapeutics Acquires Spyre Therapeutics: A Step Forward in Advancing IBD Treatments
This week in the biotech sector, Austin-based clinical-stage biotechnology company, Aeglea BioTherapeutics Inc. (“Aeglea”), (NASDAQ: AGLE), announced the completion of the acquisition of Spyre Therapeutics Inc. (“Spyre”), a privately held biotech company dedicated to advancing the treatment of inflammatory bowel disease (IBD). The Acquisition: A Strategic Move In a strategic acquisition, Aeglea fortifies its foothold…